Evidence map›Paper›PMID 30948924›Full record

ArticleMarmara pharmaceutical journal2013

Etodolac Thiosemicarbazides: A novel class of hepatitis C virus NS5B polymerase inhibitors.

Pelin Çıkla, Payal Arora, Amartya Basu, Tanaji T Talele, Neerja Kaushik-Basu, Ş Güniz Küçükgüzel

Open access · greenAbstract read
In one paragraph

Article in Marmara pharmaceutical journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pelin ÇıklaMarmara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, İstanbul, Turkey.
Payal AroraUMDNJ-New Jersey Medical School, Department of Biochemistry and Molecular Biology, New Jersey, USA.
Amartya BasuUMDNJ-New Jersey Medical School, Department of Biochemistry and Molecular Biology, New Jersey, USA.
Tanaji T TaleleSt. John's University College of Pharmacy and Health Sciences, Department of Pharmaceutical Sciences, New York, USA.
Neerja Kaushik-BasuUMDNJ-New Jersey Medical School, Department of Biochemistry and Molecular Biology, New Jersey, USA.
Ş Güniz KüçükgüzelMarmara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, İstanbul, Turkey.
Marmara University · TR

Funding

Molecular Modulators of HCV ReplicationR01DK066837 · NIDDK · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KAUSHIK-BASU, NEERJA · 2004 to 2007
$1.1M
NIDDK NIH HHS R01 DK066837
6 · The paper itself

Abstract

A novel series of new etodolac hydrazide derivatives, 1-[2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-

Indexed as

etodolacHepatit C NS5B polymerasepyrano[3,4-b]indolethiosemicarbazide

Identifiers

PMID30948924
PMCPMC6445542
OpenAlexW2010600886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.